| Literature DB >> 7365938 |
H Y Yap, C K Tashima, G R Blumenschein, G N Hortobagyi, N Eckles.
Abstract
An analysis of 29 chemotherapeutic trials in 18 male patients with advanced breast cancer disclosed an overall response rate of 44%. Most of these chemotherapeutic trials consisted of single-agent regimens, namely, fluorouracil, methotrexate, thiotepa, cyclophosphamide, and melphalan. Our data suggest that responsiveness of advanced male breast cancer to systemic chemotherapeutic agents is the same as that reported for advanced female breast cancer.Entities:
Mesh：
Substances：
Year: 1980 PMID： 7365938
Source DB: PubMed Journal: JAMA ISSN： 0098-7484 Impact factor: 56.272